Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

Nature

Volumn 523, Issue 7561, 2015, Pages 431-436

  Kondo, Asami ^a   Shahpasand, Koorosh ^a   Mannix, Rebekah ^b   Qiu, Jianhua ^b   Moncaster, Juliet ^c   Chen, Chun Hau ^a   Yao, Yandan ^a   Lin, Yu Min ^a   Driver, Jane A ^a,d   Sun, Yan ^a   Wei, Shuo ^a   Luo, Man Li ^a   Albayram, Onder ^a   Huang, Pengyu ^a   Rotenberg, Alexander ^a   Ryo, Akihide ^e   Goldstein, Lee E ^c   Pascual Leone, Alvaro ^f   McKee, Ann C ^c   Meehan, William ^g   Zhou, Xiao Zhen ^a   Lu, Kun Ping ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g Harvard Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIS P TAU; MONOCLONAL ANTIBODY; TAU PROTEIN; UNCLASSIFIED DRUG; EPITOPE; PHOSPHOPROTEIN;

ANTIBODY; APOPTOSIS; BRAIN; DISEASE; ENVIRONMENTAL RISK; HOMINID; INJURY; NEUROLOGY; PATHOLOGY; PROTEIN; RISK FACTOR; RODENT;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; TAUOPATHY; TRAUMATIC BRAIN INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; BIOSYNTHESIS; BRAIN; BRAIN INJURIES; CHEMISTRY; COMPLICATION; DISEASE MODEL; IMMUNOLOGY; MALE; METABOLISM; NERVE FIBER; PATHOLOGY; PHYSIOLOGICAL STRESS; TAUOPATHIES;

MUS;

ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; AXONS; BRAIN; BRAIN INJURIES; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; HUMANS; MALE; MICE; PHOSPHOPROTEINS; STRESS, PHYSIOLOGICAL; TAU PROTEINS; TAUOPATHIES;

EID: 84937849044     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14658     Document Type: Article

References (58)

1. Faul, M., Xu, L., Wald, M. M. & Coronado, V. G. Traumatic brain injury in the United States: emergency department visits, hospitalizations, and deaths, 2002-2006. http://www.cdc.gov/traumaticbraininjury/tbi-ed.html (Centers for Disease Control and Prevention, 2010).
2. Centers for Disease Control and Prevention. CDC grand rounds: reducing severe traumatic brain injury in the United States. MMWR Morb. Mortal. Wkly Rep. 62, 549-552 (2013).
3. Tanielian, T. et al. Invisible wounds of war: psychological and cognitive injuries, their consequences, and services to assist recovery. http://www.rand.org/pubs/monographs/MG720 (RAND Corporation, 2008).
4. Omalu, B. I. et al. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery 57, 128-134 (2005).
5. Goldstein, L. E. et al. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci. Transl. Med. 4, 134ra160 (2012).
6. McKee, A. C. et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 136, 43-64 (2013).
7. Smith, D. H., Johnson, V. E. & Stewart, W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nature Rev. Neurol. 9, 211-221 (2013).
8. De Kosky, S. T., Blennow, K., Ikonomovic, M. D. & Gandy, S. Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nature Rev. Neurol. 9, 192-200 (2013).
9. Blennow, K., Hardy, J. & Zetterberg, H. The neuropathology and neurobiology of traumatic brain injury. Neuron 76, 886-899 (2012).
10. Mortimer, J. A. et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEMRisk Factors Research Group. Int. J. Epidemiol. 20 (Suppl. 2), S28-S35 (1991).
11. Guo, Z. et al. Head injury and the risk of AD in the MIRAGE study. Neurology 54, 1316-1323 (2000).
12. Nordström, P., Michaelsson, K., Gustafson, Y. & Nordström, A. Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann. Neurol. 75, 374-381 (2014).
13. Ballatore, C., Lee, V. M. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Rev. Neurosci. 8, 663-672 (2007).
14. Mandelkow, E. M. & Mandelkow, E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb. Perspect. Med. 2, a006247 (2012).
15. Clavaguera, F. et al. Transmission and spreading of tauopathy in transgenicmouse brain. Nature Cell Biol. 11, 909-913 (2009).
16. de Calignon, A. et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685-697 (2012).
17. Liu, L. et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302 (2012).
18. Clavaguera, F. et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice. Acta Neuropathol. 127, 299-301 (2014).
19. Clavaguera, F., Hench, J., Goedert, M. & Tolnay, M. Invited review: prion-like transmission and spreading of tau pathology. Neuropathol. Appl. Neurobiol. 41, 47-58 (2015).
20. Asuni, A. A., Boutajangout, A., Quartermain, D. & Sigurdsson, E. M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129 (2007).
21. Rosenmann, H. Immunotherapy for targeting taupathology in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 10, 217-228 (2013).
22. Sigurdsson, E. M. Tau immunotherapy and imaging. Neurodegener. Dis. 13, 103-106 (2014).
23. Smith, C., Graham, D. I., Murray, L. S. & Nicoll, J. A. Tau immunohistochemistry in acute brain injury. Neuropathol. Appl. Neurobiol. 29, 496-502 (2003).
24. Johnson, V. E., Stewart, W. & Smith, D. H. Widespread tau and amyloid-beta pathologymany years after a single traumatic brain injury in humans. Brain Pathol. 22, 142-149 (2012).
25. Mannix, R. et al. Clinical correlates in an experimental model of repetitive mild brain injury. Ann. Neurol. 74, 65-75 (2013).
26. Lu, K. P., Hanes, S. D. & Hunter, T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 380, 544-547 (1996).
27. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P. & Lu, K. P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399, 784-788 (1999).
28. Zhou, X. Z. et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 6, 873-883 (2000).
29. Liou, Y.-C. et al. Role of the prolyl isomerase Pin1 in protecting against agedependent neurodegeneration. Nature 424, 556-561 (2003).
30. Pastorino, L. et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 440, 528-534 (2006).
31. Lu, K. P. & Zhou, X. Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and human disease. Nature Rev. Mol. Cell Biol. 8, 904-916 (2007).
32. Lim, J. et al. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J. Clin. Invest. 118, 1877-1889 (2008).
33. Lee, T. H., Pastorino, L. & Lu, K. P. Peptidyl-prolyl cis-trans isomerase Pin1 in aging, cancer and Alzheimer's disease. Expert Rev. Mol. Med. 13, e21 (2011).
34. Driver, J. A., Zhou, X. Z. & Lu, K. P. Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer's disease. Biochim. Biophys. Acta. http://dx.doi.org/10.1016/j.bbagen.2014.12.025 (2015).
35. Chen, C. H. et al. Pin1 cysteine-113 oxidation inhibits its catalytic activity and cellular function in Alzheimer's disease. Neurobiol. Dis. 76, 13-23 (2015).
36. Lee, T. H. et al. Death associated protein kinase 1 phosphorylates Pin1 and inhibits its prolyl isomerase activity and cellular function. Mol. Cell 42, 147-159 (2011).
37. Kim, B. M. et al. Death-associated protein kinase 1 has a critical role in aberrant tau protein regulation and function. Cell Death Dis. 5, e1237 (2014).
38. Ma, S. L. et al. A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol. Aging 33, 804-813 (2012).
39. Wijsman, E. M. et al. Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2. Am. J. Hum. Genet. 75, 398-409 (2004).
40. Luna-Muñoz, J., Chavez-Macias, L., Garcia-Sierra, F. & Mena, R. Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J. Alzheimers Dis. 12, 365-375 (2007).
41. Hampel, H. et al. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45, 30-40 (2010).
42. Nakamura, K. et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 149, 232-244 (2012).
43. Lasagna-Reeves, C. A. et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 26, 1946-1959 (2012).
44. Johnson, V. E., Stewart, W. & Smith, D. H. Axonal pathology in traumatic brain injury. Exp. Neurol. 246, 35-43 (2013).
45. Congdon, E. E., Gu, J., Sait, H. B. & Sigurdsson, E. M. Antibody uptake into neurons occurs primarily via clathrin-dependent Fcc receptor endocytosis and is a prerequisite for acute tau protein clearance. J. Biol. Chem. 288, 35452-35465 (2013).
46. Mallery, D. L. et al. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl Acad. Sci. USA 107, 19985-19990 (2010).
47. Cruz, J. C., Tseng, H. C., Goldman, J.A., Shih, H. & Tsai, L. H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483 (2003).
48. Williams, S. et al. In situ DNA fragmentation occurs inwhitematter upto12months after head injury in man. Acta Neuropathol. 102, 581-590 (2001).
49. Adhikari, A., Topiwala, M. A. & Gordon, J. A. Single units in the medial prefrontal cortex with anxiety-related firing patterns are preferentially influenced by ventral hippocampal activity. Neuron 71, 898-910 (2011).
50. Schwarzbold, M. L. et al. Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J. Neurotrauma 27, 1883-1893 (2010).
51. Tokuoka, H. et al. Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures ofembryo rat cortical neurons. J. Cell Sci. 113, 1059-1068 (2000).
52. Shahpasand, K. et al. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J. Neurosci. 32, 2430-2441 (2012).
53. Farah, C. A. et al. Tau interacts with Golgi membranes and mediates their association with microtubules. Cell Motil. Cytoskeleton 63, 710-724 (2006).
54. Ishihara, T. et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751-762 (1999).
55. Dawson, H. N. et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114, 1179-1187 (2001).
56. Meehan, W. P. III, Zhang, J., Mannix, R. & Whalen, M. J. Increasing recovery time between injuries improves cognitive outcome after repetitive mild concussive brain injuries in mice. Neurosurgery 71, 885-892 (2012).
57. Walf, A. A. & Frye, C. A. The use of the elevated plus maze as an assay of anxietyrelated behavior in rodents. Nature Protocols 2, 322-328 (2007).
58. Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 11, 47-60 (1984).